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Abstract
The vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a murine agonist of the stimulator of
interferon genes (STING), appears to target the tumor vasculature primarily as a result of stimulating pro-inflammatory
cytokine production from tumor-associated macrophages (TAMs). Since there were relatively few reports of DMXAA effects
in genetically-engineered mutant mice (GEMM), and models of non-small cell lung cancer (NSCLC) in particular, we
examined both the effectiveness and macrophage dependence of DMXAA in various NSCLC models. The DMXAA responses
of primary adenocarcinomas in K-rasLA1/+ transgenic mice, as well as syngeneic subcutaneous and metastatic tumors,
generated by a p53R172HDg/+; K-rasLA1/+ NSCLC line (344SQ-ELuc), were assessed both by in vivo bioluminescence imaging as
well as by histopathology. Macrophage-dependence of DMXAA effects was explored by clodronate liposome-mediated
TAM depletion. Furthermore, a comparison of the vascular structure between subcutaneous tumors and metastases was
carried out using micro-computed tomography (micro-CT). Interestingly, in contrast to the characteristic hemorrhagic
necrosis produced by DMXAA in 344SQ-ELuc subcutaneous tumors, this agent failed to cause hemorrhagic necrosis of
either 344SQ-ELuc-derived metastases or autochthonous K-rasLA1/+ NSCLCs. In addition, we found that clodronate liposome-
mediated depletion of TAMs in 344SQ-ELuc subcutaneous tumors led to non-hemorrhagic necrosis due to tumor feeding-
vessel occlusion. Since NSCLC were comprised exclusively of TAMs with anti-inflammatory M2-like phenotype, the ability of
DMXAA to re-educate M2-polarized macrophages was examined. Using various macrophage phenotypic markers, we found
that the STING agonists, DMXAA and the non-canonical endogenous cyclic dinucleotide, 2939-cGAMP, were both capable of
re-educating M2 cells towards an M1 phenotype. Our findings demonstrate that the choice of preclinical model and the
anatomical site of a tumor can determine the vascular disrupting effectiveness of DMXAA, and they also support the idea of
STING agonists having therapeutic utility as TAM repolarizing agents.
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Introduction
Strategies targeting the tumor vasculature represent an attrac-
tive approach in cancer therapy, and as such there has been much
interest in a class of drugs known as vascular disrupting agents
(VDA) [1,2]. The VDA, 5,6-dimethylxanthenone-4-acetic acid
(DMXAA; a.k.a. ASA-404) specifically targets immature and
unstable vasculature of solid tumors, leading to thrombosis,
hemorrhage, and necrosis [3]. In a host of preclinical studies
involving many different tumor types and primarily in subcuta-
neous tumor models, DMXAA has demonstrated potent anti-
tumor activity [4–6]. In addition, synergies were observed when
DMXAA was used in conjunction with cytotoxic chemotherapeu-
tic agents that targeted the viable rim of tumor cells that typically
survive DMXAA treatment [3,7–9].
There is evidence that the actions of DMXAA on tumor
vasculature involve both direct and indirect effects, via targeting of
the endothelium, and macrophages, respectively. The latter
appear to be the most important, and are the result of
DMXAA-triggered release of tumor-associated macrophage
(TAM)-derived factors, such as TNF-a and NO [5,7,10–12],
together with contributions from various other cytokines and
chemokines [2,6–8]. Following success in preclinical studies, the
impetus for moving DMXAA into a Phase III trial for NSCLC
PLOS ONE | www.plosone.org 1 June 2014 | Volume 9 | Issue 6 | e99988
stemmed largely from the observed increase in overall survival
reported in a previous Phase II trial [13,14]. However, the larger
trial, and other Phase II trials, failed to produce favorable
outcomes [15–17]. This raised the question as to why there was
such a discrepancy between the positive results obtained using pre-
clinical animal models and the results in the clinic. Recently, it was
shown that DMXAA exhibits differential effects on murine and
human macrophages [18], and also that the stimulator of
interferon genes (STING), was a receptor for DMXAA [19–21].
The finding that DMXAA was unable to activate human STING
provided a salient explanation for the failure of this agent in the
human clinical trials [20,21].
With the goal of gaining further insight into additional variables
accounting for the differential effects of DMXAA between pre-
clinical and clinical trials, we examined the effects of this agent in
several mouse models, including: (a) syngeneic subcutaneous and
metastatic tumors due to a cell line (344SQ-ELuc) derived from
the p53R172HDg/+ K-rasLA1/+ genetically engineered mutant mouse
(GEMM) model of NSCLC [22–24]; (b) primary lung adenocar-
cinomas arising in the K-rasLA1/+ model of NSCLC; and (c)
subcutaneous and metastatic tumors due to the human MDA-MB-
231 breast cancer cell line [25]. Consistent with previous pre-
clinical studies, DMXAA led to massive hemorrhagic necrosis in
subcutaneously grown breast cancer and NSCLC cell line tumors.
In contrast, neither autochthonic lung adenocarcinomas arising in
K-rasLA1/+ transgenic mice [26], nor metastases derived from
intracardiac injections of syngeneic 344SQ-ELuc NSCLC cells
showed responses to DMXAA administration. In addition, we
found that clodronate liposome-mediated macrophage depletion
[27] abrogated DMXAA-induced intra-tumoral hemorrhagic
necrosis in 344SQ-ELuc subcutaneous tumors.
Although the macrophage-derived factors thought to mediate
the anti-tumor effects of DMXAA are characteristic of M1
polarized cells, we found that the murine NSCLC TAMs were
primarily M2-like. Thus, the responses of M1 and M2 macro-
phages to DMXAA were investigated. We found that M2
polarized bone marrow-derived macrophages, as well as M2-like
TAMs could be re-polarized to an M1 phenotype by DMXAA.
We further found that the endogenous STING ligand, 2939-
cGAMP, produced a similar repolarization phenotype. TAM re-
education represented a plausible mechanism whereby M2-like
TAMs were able to mediate vascular disruption in response to
DMXAA. Our results lend support to the idea of using STING
agonists as TAM repolarizing agents, and they also highlight the
importance of testing agents on a variety of preclinical models. In
addition, our study highlights the growing awareness of the utility
of GEMMs for preclinical drug studies [28,29].
Results
NSCLC TAMs and Clodronate Liposome-mediated TAM
Depletion
Consistent with the evidence that macrophages play an
important role in the action of DMXAA [11,30], we found that
344SQ-ELuc subcutaneous tumors contained large numbers of
infiltrating macrophages, as detected by ionized Ca2+-binding
adaptor (Iba)-1 immunostaining. These cells were concentrated
primarily at the tumor periphery (Figure 1A), and the vast
Figure 1. Effectiveness of clodronate-mediated TAM depletion varied depending on tumor site. Representative 344SQ-ELuc
subcutaneous tumor sections were stained with antibodies against Iba-1 (A) and Arg-1 (B), demonstrating abundant M2-like macrophages primarily
at the tumor periphery. In contrast, much lower and variable macrophage infiltration was present in either the K-rasLA1/+ primary NSCLCs (C) or in
344SQ-ELuc metastases (D). (E) MTT assay conducted on BMDM (Mw) or 344SQ-ELuc cells to assess potential cytotoxicity in response to either
Clodrolip (Clod) or empty liposomes (EL). (F) Representative 344SQ-ELuc subcutaneous tumor and kidney metastases sections from Clod-treated mice
were stained with Iba-1 showing that TAM depletion only occurred in subcutaneous tumors (T = tumor, K = kidney). Scale bar = 100 mm (A–B) 50 mm
(C, D, F). Data represent the mean 6 SEM.
doi:10.1371/journal.pone.0099988.g001
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majority of the TAMs were positive for the murine M2 marker,
arginase (Arg)-1 (Figure 1B). In contrast, spontaneously arising K-
rasLA1/+ lung adenocarcinomas contained a relative paucity of
TAMs, with only a few scattered cells located at the tumor
periphery (Figure 1C). To obtain metastases, 344SQ-ELuc
NSCLC cells were introduced via intracardiac, left-ventricle
(LV), injection in syngeneic mice. This route reproducibly resulted
in multiple kidney, adrenal gland, lung, and visceral fat pad
metastases (Figure S1). These metastases contained variable
levels of macrophage infiltration (Figure 1D) but at considerably
lower levels than were observed in the 344SQ-ELuc subcutaneous
tumors.
To investigate the role of macrophages in mediating DMXAA
vascular disruption, we depleted macrophages using clodronate-
encapsulated liposomes (Clodrolip) [27]. A comparison of the
effects of in vitro Clodrolip treatment of 344SQ-ELuc cells and
bone marrow-derived macrophages (BMDM) demonstrated an
,100-fold greater sensitivity of macrophages (Figure 1E). In vivo,
Clodrolip led to an ,50% decrease in CD11b+ F4/80+ marrow
cell populations (Figure S2A–B), and although we obtained
,100% depletion of TAMs within subcutaneous 344SQ-ELuc
tumors, no evidence of TAM depletion was seen in 344SQ-ELuc
metastases (Figure 1F). TAMs can play a supportive role during
tumor development, and consistent with this, we found that
Clodrolip-mediated TAM depletion slowed the growth of 344SQ-
ELuc subcutaneous tumors while growth of metastases was
unaffected, presumably due to the inability to obtain macrophage
depletion (Figure S2C–F).
Depletion of Macrophages in Subcutaneous 344SQ-ELuc
Tumors Alters the Response to DMXAA
Consistent with previous reports [22], 344SQ-ELuc NSCLC
subcutaneous tumors respond dramatically to DMXAA, with a
marked (,2-logs) decrease in bioluminescence (BLI) signals post-
Figure 2. TAM depletion prevented DMXAA-induced hemorrhagic necrosis of subcutaneous NSCLC. (A) BLI of bilateral 344SQ-ELuc
subcutaneous tumors in a representative syngeneic 129/Sv mouse at day 14 post-cell injection. Mice were randomized into two groups and
administered a single i.p. dose of 25 mg/kg DMXAA or DMSO vehicle and imaged again at 6 and 24 hours (N = 10). Regions of interest (ROIs) drawn
over tumors or whole body, to quantify photon emission rates, revealed a dramatic loss of signal intensity following DMXAA treatment of mice with
subcutaneous tumors. (B) (**p#0.01). (C) Histology of representative subcutaneous tumors taken at 24 hours post-DMXAA treatment demonstrated
hemorrhagic rims and necrosis (scale bars = 100 mm). (D) 344SQ-ELuc subcutaneous tumors were established in Clod or EL treated mice which were
then given DMXAA or vehicle control (N = 6 Clod plus DMXAA; N= 3 controls). Quantification of ROI demonstrated a significant drop in photon
emission rates in response to DMXAA (*p,0.05). (E) Histology of representative tumors at 24 hours demonstrates absence of hemorrhage at the
tumor periphery in the Clod plus DMXAA treated mice, however, necrosis still occurred (*) (scale bar = 100 mm). (F) Representative gross pathology of
subcutaneous 344SQ-ELuc tumors following DMXAA treatment, showing extensive hemorrhage both within and in the immediate vicinity of the
tumor. Note that Clod plus DMXAA treated tumors did not exhibit intra-tumoral hemorrhage, but rather showed thrombosis and hemorrhage
confined to larger feeding vessels (yellow asterisk). Data represent the mean 6 SEM.
doi:10.1371/journal.pone.0099988.g002
STING Agonists Cause M2-To-M1 Repolarization
PLOS ONE | www.plosone.org 3 June 2014 | Volume 9 | Issue 6 | e99988
drug injection (Figure 2A–B). This was accompanied by vascular
thrombosis and hemorrhage in the tumor periphery, and by the
development of extensive central necrosis (Figure 2C). The drop
in BLI following DMXAA treatment was not due to direct tumor
cell toxicity since DMXAA had no detrimental effect on 344SQ-
ELuc cell viability (Figure S3). Instead, tumor BLI signal loss was
attributable to greatly diminished blood, and hence luciferin
substrate, perfusion which would diminish ATP-dependent light
production. While decreased perfusion could conceivably have
resulted from reversible vasoconstriction, given the massive tumor
necrosis observed, it was more likely that decreased light emission
was the result of tumor vessel thrombosis and rupture.
Since TAMs could be efficiently depleted by Clodrolip in the
344SQ-ELuc subcutaneous tumors, we evaluated the responses of
these tumors to DMXAA. Mice treated with empty liposomes (EL)
served as the control group. DMXAA still provoked a dramatic
drop (,2-logs) in bioluminescence signal intensity (Figure 2D),
however, this occurred in the absence of the characteristic intra-
tumoral thrombosis and hemorrhage. Instead, DMXAA led to
massive non-hemorrhagic, ‘dry’, necrosis (Figure 2E). The latter
appeared to result from DMXAA-induced occlusion of tumor-
feeding vessels (Figure 2F). Although it was conceivable that
Clodrolip had sensitized the feeding vessels to DMXAA, this result
suggested the VDA effects of DMXAA were not confined to the
intra-tumoral vasculature, but rather that tumor-feeding arterioles
had also been compromised by this agent. Indeed, DMXAA may
have a direct effect on endothelial cells [3,7–9]. While it is
plausible that clodronate treatment may have sensitized the tumor
vasculature, for example, by increasing vessel fragility or
interfering with pericyte coverage, we have found that large
tumor-feeding vessel thrombosis is also present after DMXAA
administration to non-Clodrolip exposed mice (data not shown).
The results suggest that DMXAA mediates its effects in two ways:
by causing macrophage-induced intra-tumoral microvessel disrup-
tion and by causing thrombosis of tumor-feeding vessels.
Regardless, it was clear that subcutaneous 344SQ-ELuc tumor
TAM depletion was effective in preventing DMXAA-induced
intra-tumoral hemorrhagic thrombosis.
Both DMXAA and the Non-canonical Cyclic Dinucleotide
2939-cGAMP are able to Re-educate M2 Macrophages
towards an M1 Pro-inflammatory Phenotype
Since the intra-tumoral hemorrhagic response of subcutaneous
344SQ-ELuc tumors to DMXAA was dependent on TAMs, we
next examined the effect of DMXAA directly on macrophages.
DMXAA is known to stimulate the production of cytokines, such
as TNFa, CXCL10 (IP-10), MIP-1a, and MIP-1b, [7,10], in order
to mediate vascular disruption, and these factors are typical of M1
macrophage responses. However, we found that the majority of
344SQELuc TAMs were M2-like (Figure 1A–B). Hypothesizing
that DMXAA would alter macrophage polarization, supernatant
cytokine and chemokine profiles of DMXAA-treated BMDM M1-
and M2-polarized macrophages (Figure S4 A) were evaluated by
a cytokine/chemokine discovery array. The top fold-changed
cytokines are listed in Table 1 (for the raw data see Table S1).
Although the majority of the up-regulated cytokines were
characteristic of M1-polarized cells (e.g. CXCL10, CXCL9, IL-
1a and b), we also found that compared to the M1 cells, the IL-4
polarized M2 macrophages displayed 2–10 fold greater inductions
of these factors in response to DMXAA, indicative of their re-
education towards an M1 phenotype [31–33]. Furthermore,
analysis of RNA transcripts provided additional evidence that
M2 macrophages had been shifted towards an M1 phenotype, as
demonstrated by decrease in the M2 markers, Arg-1 and Fizz1,
and acquisition of the M1 markers, iNOS and IL-12p40
(Figure 3A). The repolarizing effect of DMXAA was even
evident at relatively low concentrations (e.g. 5 mg/ml) of this agent
(Figure 3B). Consistent with STING-TBK1 pathway activation
[34], by reverse-phase protein array, we found that DMXAA-
mediated upregulation of the NF-kB pathway as shown by
increased p65 phosphorylation in M2 macrophages (Figure S4B).
Since one of the targets of DMXAA is murine STING, we
tested another STING agonist, the non-canonical endogenous
cyclic dinucleotide 2939-cGAMP [35,36] on M2 macrophages. As
was the case with DMXAA, we found that 2939-cGAMP
administration to M2-polarized macrophages dramatically in-
creased interferon-b, as well as expression of M1 markers iNOS
and IL-12p40, and this was accompanied by decreased expression
of the M2 markers, Arg-1 and Fizz1 (Figure 3C–D). Together,
Table 1. DMXAA-induced factors in M1- and M2-polarized BMDMs.
M1 + DMXAA M2 + DMXAA
Factor (fold change ± SEM) (fold change ± SEM)
IL-1a [1.060.3] 1.9602
IL-1b 1.960.4 2.861.2
IL-6 4.160.4 1.260.4
IP-10 (CXCL10) 36.562.3 357.5618.4**
MCP-1 (CCL2) 6.960.6 9.662.2
MIG (CXCL9) 1.160.004 43.9622.7
MIP-1a 17.362.7 76.6619.9
MIP-1b 109.9614.1 247.8641.8
RANTES (CCL5) 1.160.05 181.8648.8
TNF-a 2.460.3 5.861.5
VEGF [1.860.4] [2.560.9]
Note: Brackets indicate a negative fold-change (**p#0.01).
doi:10.1371/journal.pone.0099988.t001
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our results using these chemically distinct agonists indicated that
STING activation was the key factor responsible for the observed
M2-to-M1 macrophage re-education.
RNA transcripts from spleens of mice treated in vivo with
DMXAA also demonstrated induction of iNOS and down-
regulation of Arg-1 (Figure 4A), as well as diminished anti-Arg-
1 immunohistochemical staining (Figure 4B). Importantly,
subcutaneous tumor lysates also demonstrated evidence of
DMXAA-mediated repolarization (Figure 4C), with diminished
Arg-1 staining being evident as early as 6 hours post-DMXAA
exposure (Figure 4D). In summary, these results suggest that
STING activation can mediate M2-like TAM re-education.
Discordant Effects of DMXAA on 344SQ-ELuc
Subcutaneous Versus Metastatic Tumors
In contrast to the dramatic results obtained using 344SQ-ELuc
subcutaneous tumors, DMXAA treatment of 344SQ-ELuc me-
tastases yielded no decrease in photon emission rates (Figure 5A–
B), with the tumors remaining histologically similar to controls
after this treatment (Figure 5C). To confirm this effect was not
peculiar to the 344SQ-ELuc cell line, we also compared the effects
of DMXAA on subcutaneous versus metastatic tumors generated
in MDA-MB-231-Luc2 human breast cancer xenografts. Similar
to 344SQ-Eluc tumors, the MDA-MB-231-Luc2 model demon-
strated dramatic hemorrhagic necrosis of subcutaneous tumors but
not bone metastases (Figure 6).
Subcutaneous tumors grow rapidly up to ,1 cm3, whereas the
multiple metastases generated by 344SQ-ELuc cells are not able of
reach this size owing to the lethal tumor burden that would ensue.
Therefore, we evaluated the effect of DMXAA on subcutaneous
344SQ-ELuc tumors having a size (,2 mm3) comparable to that
of the metastases. As with the large subcutaneous tumors,
DMXAA administration to mice with small subcutaneous tumors
still led to ,2-log decreases in photon emission at both 6 and 24
hours (Figure 5D–E). This was also accompanied by the
development of pathology similar to that of the large subcutaneous
Figure 3. Exposure to either DMXAA or 2939-cGAMP repolarized M2 macrophages towards an M1 phenotype in vitro. (A) Triplicate
samples of non-polarized macrophages (Mw), M1-, and M2-polarized macrophages were exposed to 20 mg/ml DMXAA for 24 hours in vitro and RNA
transcript levels measured by qRT-PCR. DMXAA down-regulated Arg-1 and Fizz1 expression, while increasing expression of iNOS and IL-12p40. (B)
Shows reciprocal changes in Arg-1 and iNOS expression in M2 cells in response to increasing concentrations of DMXAA (N=3). (C) RNA transcripts
were also taken from triplicate samples of M2-polarized macrophages exposed to 20 or 40 mg/ml 2939-cGAMP plus LF2000 for 6 and 24 hours in vitro.
LF2000 alone served as the control (designated as ‘M2 alone’ in the graphs). 2939-cGAMP led to down-regulation of Arg-1 and Fizz1, and dramatic
increases in iNOS and IL-12p40 expression in a dose-dependent manner. (D) IFN-b induction provided an indication of STING activation in response
to 2939-cGAMP, with strong inductions at 6 hours that returned to baseline by 24 hours (*p,0.05, **p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0099988.g003
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tumors (Figure 5F). Thus, differences in tumor volume did not
account for the differential effects of DMXAA on subcutaneous
versus metastatic tumors.
Primary Pulmonary Adenocarcinomas Arising in K-Rasla1/+
Transgenic Mice Show No Response to DMXAA
We next evaluated the effects of DMXAA on spontaneously
arising primary NSCLCs in the K-rasLA1/+ transgenic model [26]
of lung cancer. Again, in contrast to the dramatic results seen with
the subcutaneous tumors, DMXAA treatment of K-rasLA1/+ mice
(,150 days old) produced no discernable histological effect on the
lung adenocarcinomas (Figure 7A). It was possible that the
variable level of macrophage infiltration amongst different tumor
sites may have accounted for the inconsistent responses to
DMXAA. Thus, while primary K-rasLA1/+ lung tumors have even
fewer numbers infiltrating macrophages (Figure 1C) than
systemic metastases, subcutaneous tumors show abundant infil-
trates of macrophages and neutrophils (data not shown) in the
tumor periphery (Figure 7B). Thus, the level of TAM infiltration
could be one potential variable determining whether DMXAA will
cause vascular disruption and hemorrhagic necrosis.
Primary NSCLC Tumors Exhibit Increased Evans Blue Dye
Permeability
DMXAA is known to target the unstable, leaky vasculature of
tumors [3,7–9], thus, we investigated whether diminished perme-
ability might be a potential factor rendering the primary tumor
vasculature resistant to DMXAA. Using a modified Miles assay,
we injected mice with the Evans blue dye to look for interstitial
leakage in K-rasLA1/+ lung adenomas and adenocarcinomas, and in
344SQ-ELuc subcutaneous tumors. Primary lung neoplasms
(adenomas and adenocarcinomas) demonstrated similar dye
permeability as subcutaneous tumors (Figure 8A). Frozen sections
of K-rasLA1/+ lung (Figure 8B), and subcutaneous tumors
(Figure 8C) demonstrated similar dye leakage into tumors at
both sites (see also Figure S5). Hence, the possibility that vessel
impermeability to small molecules such as DMXAA was a factor
accounting for the inability of this agent to cause vascular
disruption in the primary tumors was discounted.
Subcutaneous and Metastatic 344SQ-Eluc Tumors Exhibit
Differences in Vasculature Structure
Since differences in tumor vascular bed structure could be a
factor accounting for the differential responses to DMXAA, we
compared subcutaneous 344SQ-ELuc tumors and p53R172HDg/+ K-
rasLA1/+ lung adenocarcinoma-derived spontaneous metastases
using a 3D-microcomputed tomography (micro-CT) imaging
quantification method we previously described [22]. Interestingly,
3D renderings of 344SQ-ELuc subcutaneous tumors and
p53R172HDg/+ K-rasLA1/+ metastases displayed significant differences
with respect to overall appearance (Figure 9A), vessel thickness
(Figure 9B), and most strikingly, with respect to internal
avascular areas, as demonstrated by a sphere-filling computational
technique [22] (Figure 9C). Quantification of vessel parameters
demonstrated a significant drop in vessel density (VV/TV)
(Figure 9D) as well as overall vessel number (V.N) and
connectivity (Conn.D) in subcutaneous tumors (Figure S6).
Interestingly, there was a similar pattern in vessel thickness
(V.Th) when compared as a percentage of vessels present,
although the metastases had larger-diameter vessels (Figure 9E).
Vessel separation (V.Sp), on the other hand, demonstrated a
significant difference between the two different tumor sites, with
subcutaneous tumors having markedly less small-diameter spheres
(an indication of well vascularized areas) (Figure 9F), thus
confirming the presence of larger avascular/ischemic areas in the
subcutaneous tumors (as visualized by the red spheres in
Figure 9C). Thus, it was plausible that differences in the structure
of the tumor vascular network between the different tumor sites
might also contribute to the differential responses to DMXAA.
Discussion
Our findings using both DMXAA and 2939-cGAMP suggest
that STING activation was the common factor leading to M2
macrophage re-polarization, a process that undoubtedly played a
role in mediating the vascular disrupting effects of DMXAA we
observed on the subcutaneous 344SQ-ELuc tumors. Interestingly,
however, we found that the vascular disrupting effects of DMXAA
on subcutaneous tumors did not extend to either the 344SQ-ELuc
metastases obtained following intracardiac injection of these cells,
Figure 4. Evidence of DMXAA-mediated macrophage repolarization in vivo. (A) Spleen lysates from mice treated with 25 mg/kg DMXAA
(N= 3), versus DMSO vehicle (N = 4) demonstrated decreased Arg-1, and elevated iNOS, transcripts. (B) Representative histology of spleen showing
Arg-1 down-regulation in vivo in response to DMXAA. (C) 344SQ-ELuc whole tumor lysates from mice treated with 25 mg/kg DMXAA (N= 3), or
DMSO vehicle (N= 4), also demonstrate a DMXAA-induced drop in Arg-1 and increase in iNOS transcripts. (D) Representative tumor sections stained
with anti-Arg-1 showing a drop in Arg-1 staining as early as 6 hours post DMXAA. Scale bars = 100 mm. Data are the mean 6 SEM.
doi:10.1371/journal.pone.0099988.g004
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or to the spontaneously arising tumors in the K-rasLA1/+ GEMM
model of NSCLC. Indeed, the majority of successful pre-clinical
studies evaluating the utility of DMXAA were carried out in
subcutaneous tumor models, with relatively few studies examining
the effects of DMXAA on tumors in other anatomical sites
[37,38]. Echoing our results, experiments employing a different
vascular disrupting drug, flavone acetic acid (FAA), vessel
disruption was seen in subcutaneous tumors, but not systemic
tumors [39]. Thus, although the inability of DMXAA to activate
human STING provided an obvious reason for failure of DMXAA
in human cancer trials [20,21], our results nevertheless suggest
that vascular disruption might not occur in either primary or
metastatic human NSCLC if human STING agonists were
administered. With regard to correcting this defect, considerable
efforts are now underway involving the development of stable
cyclic dinucleotide analogs that will allow human STING
activation [40].
Differences in the density of TAM infiltration amongst different
tumor sites may have been one of several factors accounting for
the differential effects of DMXAA on subcutaneous versus 344SQ-
ELuc metastases. Supporting the key role of infiltrating TAMs, we
found that their depletion in subcutaneous 344SQ-ELuc tumors
prevented DMXAA-induced intra-tumoral hemorrhagic necrosis.
In the case of 344SQ-ELuc subcutaneous tumors, TAMs were
present as a dense rim at the tumor periphery and were thus well
positioned to support DMXAA-induced vascular disruption via
the production of pro-inflammatory mediators. There were
extensive regions of ischemic necrosis invariably present within
the subcutaneous 344SQ-ELuc tumors, signifying the availability
of macrophage activating environmental factors such as hypoxia
and the Toll-like receptor (TLR) 4-activating protein, high
mobility group, HMGB1 protein [41]. Thus, in addition to
quantitative differences in macrophage infiltration density between
tumor sites, there may have been substantial qualitative differences
between the TAMs at different tumor sites.
Macrophages are inherently plastic, with the M1- and M2-
polarized phenotypes representing the extremes of a spectrum
[33,42,43]. Although TAMs are often M2-like, there is now
evidence that such TAMs can be re-polarized towards an M1
phenotype that can inhibit tumor growth [31,32,44,45]. Herein,
Figure 5. NSCLC metastases failed to show vascular disruption in response to DMXAA. (A) BLI of metastatic 344SQ-ELuc tumors prior to
DMXAA or DMSO administration and again at 6 and 24 hours (N = 6 and 8 respectively). Whole body regions of interest (ROIs) demonstrate no loss of
BLI (B). (C) Representative kidney metastases (tumor= T, kidney =K) did not show evidence of hemorrhagic necrosis after DMXAA treatment. (D–E)
BLI of 344SQ-ELuc subcutaneous tumors at day 7 (N= 6) demonstrated a considerable drop in photon emission rates after DMXAA in mice with
smaller tumors (*p,0.05), and the latter were accompanied by evidence of hemorrhagic necrosis (F).
doi:10.1371/journal.pone.0099988.g005
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we show that the STING agonists DMXAA and 2939-cGAMP are
both able to repolarize M2-polarized marrow-derived macro-
phages in vitro, and we also provide evidence that DMXAA is able
to shift M2-like macrophages towards an M1-like phenotype
in vivo. The latter results were in agreement with a recent study
reporting an M2-like to M1 shift in TAM populations in response
to DMXAA treatment that was also were accompanied by an anti-
tumor effect [46]. Intra-tumoral TAM repolarization would
provide a source of pro-inflammatory cytokines and chemokines,
and reduce the levels of vascular endothelial growth factor, effects
that could contribute towards either vascular disruption, or
stabilization, respectively. TAM re-education with STING ago-
nists may play a role in other important processes, including
promotion of anti-tumor adaptive immune responses that are
dependent on type I interferons and dendritic cell activation
[47,48].
The sensitivity of tumor vasculature to DMXAA is thought to
be due to the immature and irregular vascular patterning within
tumors [2,7]. To produce subcutaneous tumors, large numbers of
cancer cells are implanted and these divide rapidly, rendering
Figure 6. DMXAA showed differential tumor site-specific vascular disruption in a human breast cancer xenograft model. (A) BLI of
MDA-MB-231-Luc2 subcutaneous tumors in NIH-III (nu/nu; bg/bg) mice 30 days post-cell inoculation, or metastases at day 21 post-cell inoculation.
Mice were randomized into two groups (N= 10 each) and administered DMXAA or vehicle control, and then re-imaged at 6 and 24 hours. ROI
encompassing the tumors or whole body were used to quantify photon emission rates. A significant drop in signal intensity in subcutaneous tumors
treated with DMXAA, however, there was no change in light emission from DMXAA treated mice with metastatic tumors (B) (***p,0.001). (C)
Representative histology of subcutaneous tumors demonstrating the presence of massive hemorrhagic necrosis in DMXAA treated mice (scale
bar = 100 mm), with bone metastases (T = tumor, CB= cortical bone, TB = trabecular bone) showing only very limited regions of hemorrhage in
response to DMXAA (scale bar = 50 mm). (D) Anti-Iba-1 staining was used to show the presence of macrophages in both subcutaneous and metastatic
tumors. Data represent the mean 6 SEM.
doi:10.1371/journal.pone.0099988.g006
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them sensitive to chemotherapeutic agents [49]. Growth of cells
introduced in this manner may outstrip the angiogenic capacity of
the host, leading to the development of large regions of ischemia
and necrosis that can promote macrophage infiltration and
activation. In both the 344SQ-ELuc metastases and the auto-
chthonic NSCLC tumors there were no areas of necrosis, in
contrast, subcutaneous 344SQ-ELuc tumors contained large
necrotic regions and were densely populated with macrophages.
It is possible that the ischemia and necrosis that typifies
subcutaneous tumors renders their vessels more susceptible to
DMXAA. In addition, it is plausible that compared to vessels
derived from other vascular beds, dermal vasculature-derived
tumor vessels are inherently unstable, and hence more vulnerable
to DMXAA. Co-option of mature vessels may be a feature of both
systemic metastases and primary lung adenocarcinomas, and such
vessels, like other normal vascular beds in the animal, would be
predicted to be refractory to the vascular disrupting effects of
DMXAA. Our finding of structural differences in the vasculature
between tumors at different anatomical sites lends some support
the latter notion, an idea that was reinforced by the apparent
inability of clodronate liposomes to cause macrophage deletion in
344SQ-ELuc metastases. Indeed, the latter observation provided a
functional indication of structural differences between subcutane-
ous tumors and metastases. In summary, and as depicted in
Figure S7, the features of the subcutaneous 344SQ-ELuc tumor
vasculature may render them susceptible vascular disrupting
effects of DMXAA. In contrast, the 344SQ-ELuc metastases,
having arisen not only within different vascular beds, but
importantly, from a very much smaller initial tumor colonizing
cell numbers, contain vessels that are resistant to this agent.
In view of the evidence that DMXAA, acting via its effects on
TAMs and/or dendritic cells, has the capacity to augment
adaptive cytotoxic T cell anti-tumor activity, reviewed in [48], it
would be of considerable interest to determine whether chronic
administration of STING agonists might similarly lead to
spontaneous immunity against 344SQ-ELuc metastases and
primary lung adenocarcinomas. The fact that 344SQ-ELuc
metastases do not undergo hemorrhagic necrosis in response to
DMXAA would actually be of benefit in this setting, since it would
allow anti-tumor immunity to be readily quantified via changes in
photon emission rates.
Recent studies suggest GEMMs may be able to more faithfully
mimic their human counterparts, not only with respect to genetic
alterations, but also in their ability to predict responses to therapy
[28,29,50,51]. Thus, while primary orthotopic or subcutaneous
models are useful for initial drug screening, new agents also need
to be evaluated using a range of preclinical models before their use
in humans is contemplated [49]. Interestingly, we found that
metastases resulting from intra-cardiac injection of 344SQ-ELuc
cells failed to respond to DMXAA, suggesting that GEMM-
derived cell lines might serve as effective surrogates for the
corresponding slowly growing autochthonous cancers. Regardless
of whether or not STING agonists are ultimately found to cause
vascular disruption in human cancer, the potential for such agents
to repolarize TAMs will render them useful additions to the anti-
cancer armamentarium.
Materials and Methods
Mice
Male 129/Sv mice (6–12 week old) were used for syngeneic
tumor studies. Transgenic mice harboring the p53R172HDg/+ and K-
rasLA1/+ mutations were kindly provided Dr. G. Lozano (University
of Texas) [23,26,52]. Mice were maintained on standard mouse
chow (Pico-Vac Lab Mouse Diet #5062), and housed in a specific
pathogen-free barrier facility with ethics approval from the
University of Calgary Animal Care Committee (protocols
M10063 and M08112) and in accordance with Canadian Council
on Animal Care guidelines.
Cell Lines and Culture
The p53R172HDg/+ K-rasLA1/+ lung adenocarcinoma subcutane-
ous metastasis-derived 344SQ NSCLC (male) cell line, generously
provided by Dr. J. Kurie (University of Texas) [23,24], was
transfected with a EGFP-Luc2 fusion gene dual reporter as
previously described [22,25]. 344SQ-EGFP-Luc2 (designated
herein as 344SQ-ELuc) cells were cultured in RPMI 1640
(Invitrogen), supplemented with 10% FBS, 100 U/ml penicillin,
100 mg/ml streptomycin and 0.8 mg/ml geneticin (Invitrogen) in
Figure 7. DMXAA produced no evidence of vascular disruption
in spontaneous lung adenocarcinomas. (A) Representative histol-
ogy of lung adenocarcinomas in K-rasLA1/+ mice (,150 days of age)
following treatment with either vehicle (N = 3), or DMXAA (N= 6)
showing no evidence of hemorrhagic necrosis with the latter. The
responses of subcutaneous 344SQ-ELuc tumors (N= 6) to DMXAA
injection are shown for comparison purposes. (B) Tumor sections
stained with anti-Iba-1 demonstrated a thick rim of macrophages at the
tumor periphery in 344SQ-ELuc subcutaneous day 14 (top left) and day
7 (top right) tumors. In contrast, there were variable and much lower
levels of macrophage infiltration within 344SQ-ELuc metastases, for
example, in lung (bottom left) or liver (bottom right). Scale
bar = 100 mm (F, G), 50 mm (C, H). Data represent the mean 6 SEM.
doi:10.1371/journal.pone.0099988.g007
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a 37uC 5% CO2 humidified incubator. Bone marrow-derived
macrophages (BMDM) were collected from 129/Sv mice (N=3).
Cells were resuspended in DMEM (Lonza) supplemented with
100 U/ml penicillin, 100 mg/ml streptomycin, 10 mM sodium
pyruvate, 20 mM L-glutamine (Invitrogen), 10% FBS (Hyclone)
and 20% L929 cell conditioned media. BMDM were plated onto
100 mm bacterial plates and incubated at 37uC in a 5% CO2
humidified atmosphere.
Tumor Generation and Drug Treatments
To generate subcutaneous tumors, 56105 344SQ-ELuc cells in
100 ml PBS were injected in both posterior flanks of mice.
Metastatic tumors were generated via intracardiac injection of
16104 344SQ-ELuc cells in 100 ml PBS into the left ventricles
(LV) of mice anaesthetized with 100 mg/kg ketamine and 6 mg/
kg xylazine, given intra-peritoneally (i.p.). Tumor growth was
monitored every 2–4 days via BLI. Mice were shaved to minimize
light signal attenuation. Once tumors were established (day 10 for
systemic metastases; day 7 or day 14 for subcutaneous tumors),
mice were given 25 mg/kg of DMXAA (D5817, Sigma-Aldrich),
or DMSO vehicle by i.p. injection. BLI was carried out at 6 and
24 hours as previously described [22]. K-rasLA1/+ mice, aged ,150
days received 25 mg/kg DMXAA or DMSO and were sacrificed
6 hours later. TAM depletion was carried out via i.p. injection of
Clodrolip (2 mg/20 g mouse) starting at day 21 prior to tumor
cell inoculation, and was maintained with 1 mg/20 g mouse given
every 3 days for the duration of the experiment. Empty liposomes
(EL) served as the controls [27].
Breast Cancer Metastases Model
The human breast cancer cell line MDA-MB-231 was
previously transfected with a dual reporter (an EGFP-Luc2 fusion
protein) [25]. MDA-MB-231-EGFP-Luc2 cell (designated herein
as MDA-MB-231-Luc2) were cultured in Dulbecco’s modified
Eagle medium (DMEM; Invitrogen), supplemented with 10% fetal
bovine serum (FBS), 100 U/ml penicillin, 100 mg/ml streptomy-
cin and 0.8 mg/ml geneticin (Invitrogen) in a 37uC 5% CO2
humidified incubator. Athymic-beige (NIH-III) female mice (4–5
week old) were purchased from Charles River Laboratories (St.
Constant, QC) and subcutaneous tumors (analyzed at day 21)
were generated by intradermal implantations of 56105 cells in
100 ml PBS over both the right and left posterior flanks. Metastatic
tumors (analyzed at day 30) were generated via LV injection of
26105 cells in 100 ml PBS into anesthetized mice (100 mg/kg
ketamine and 6 mg/kg xylazine, given i.p.). Knees were fixed at
4uC in 4% paraformaldehyde (PFA) for 7 days, followed by
decalcification in 14% ethylenediaminetetraacetic acid (EDTA)
prior to paraffin embedding and sectioning.
Figure 8. No differences in Evans blue permeability was present between primary lung neoplasms and subcutaneous tumors. (A)
Whole-mount images of adenoma- and adenocarcinoma-bearing K-rasLA1/+ lungs and 344SQ-ELuc subcutaneous tumors following Evans Blue dye
injection, or PBS control. (B) Fluorescence images of lung sections (phase contrast shown in grey, and reflected light in red) and subcutaneous tumor
sections in (C) (Scale bar = 100 mm). The dye was able to extravasate in both tumor locations, suggesting that lack of permeability to small molecules
did not account for the failure of DMXAA to disrupt the vasculature of primary lung neoplasms.
doi:10.1371/journal.pone.0099988.g008
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Histopathology
Tumors were fixed in 10% neutral buffered formalin (NBF), and
lungs were inflated with 10% NBF via a tracheal cannula. Tissues
were processed for paraffin embedding and sectioned at 4 mm
prior to staining with hematoxylin and eosin (H&E). For
immunohistochemistry, anti-Iba1, 1:500 (Wako) anti-Arginase-1,
1:100 (Santa Cruz Biotechnology) antibodies were used, with
Vectastain IgG (ABC kit, Vector Laboratories) secondary with
DAB substrate development (Sigma-Aldrich). Hematoxylin served
as the counterstain.
Cytotoxicity Assay
Assays for DMXAA and Clodrolip cytotoxicity used 3-(4,5-
dimethyl-2-thialolyl)-2,5-diphenyl-2H-tetrazoliumbromide (MTT
reagent; Sigma, St. Louis, MO) as per instructions provided by
the manufacturer. Absorbance values were determined on a
Multiskan Ascent Microplate Reader (Thermo Labsystems, Fin-
land).
Flow Cytometry
BMDM were collected from Clodrolip or EL treated mice and
suspended in 2% FBS/PBS and incubated with Fc Block (anti-
CD16/CD32), followed by anti-CD11b (BD), and anti-F4/80
antibodies (eBioscience). Samples were run on a FACScalibur
equipped with CellQuest software (BD) and quantified using
FlowJo software (TreeStar).
Reverse Phase Protein Array (RPPA)
M2-polarized (40 ng/ml IL-4 for 48 hours, N= 3) macrophages
were treated with 20 mg/ml DMXAA or DMSO vehicle for
30 min. Cells were then lysed and protein denatured in SDS
buffer and samples sent for RPPA analysis (RPPA Core Facility,
University of Texas, MD Anderson Cancer Center, Houston,
TX). Differential abundance of various proteins and/or their
phosphorylation status in response to DMXAA was assessed.
Vascular Perfusion and Micro-computed Tomography
(micro-CT)
Mice with 344SQ-ELuc subcutaneous tumors, and aged
p53R172HDg/+ K-rasLA1/+ mice (,200 day old) with metastases were
used to evaluate the tumor vasculature. Prior to sacrifice, mice
were given a sub-lethal i.p. dose of ketamine (100 mg/kg) plus
xylazine (6 mg/kg). Cardiac perfusions with Microfil were as
previously described [22,53]. Excised tumors were scanned using a
mCT35 (Scanco Medical AG) at a nominal resolution of 10 mm (55
kVp, 145 mA, 200 ms integration time, 1000 proj/180 degrees,
20.5 mm diameter field of view, 204862048 reconstruction
matrix, cone-beam reconstruction) as previously described [22].
Vascular Permeability
Vessel permeability in mice with subcutaneous 344SQ-ELuc
tumors and aged K-rasLA1/+ mice (,200 days old) was examined
using a modified Miles Assay. Mice were given a 4 ml/g dose of
Figure 9. Differences in vascular structure were present between subcutaneous 344SQ-ELuc tumors and metastatic p53R172HDg/+ K-
rasLA1/+ NSCLC. (A) Micro-CT 3D rendering of tumors from Microfil-perfused mice harboring 344SQ-ELuc subcutaneous tumors or p53R172HDg/+ K-
rasLA1/+ lung adenocarcinoma-derived metastases (N = 6). (B) Vessel thickness (V.Th) represented by heat-map, red vessels $0.2 mm diameter (C)
Vessel separation (V.Sp) represented by the maximal sphere-filling model (red spheres indicating a diameter of $2 mm between vessels). Full view
and cut-plane through tumor center demonstrates markedly increased avascularity of subcutaneous tumors as compared to metastases. (D)
Quantification of vessel density (VV/TV) confirms significantly less vessels present in subcutaneous tumors (**p,0.01). (E) Distribution of V.Th is
represented as a percentage of total vessels, indicates similar pattern in both tumor locations (Log10 scale). (F) Distribution of average number of
spheres as an indicator of V.Sp demonstrated significantly fewer small-diameter spheres in subcutaneous tumors (***p,0.001), indicative of ischemic
and/or necrotic regions (Log10 scale). Data are represented as the mean 6 SEM.
doi:10.1371/journal.pone.0099988.g009
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2% Evans Blue dye (Sigma) made up in 0.9% saline by i.p.
injection. After 5 hours, mice were perfused with PBS followed by
4% PFA using a Masterflex C/L perfusion pump (Cole-Parmer).
Tissues were harvested and lungs were inflated via a tracheal
cannula prior to sinking them in 30% sucrose/PBS and OCT
embedding (Tissue-Tek). Whole tissues were imaged on a Stemi
SV 11 dissection microscope (Zeiss). Samples were cryosectioned
at 10 mm and imaged on an Axio Imager A2 (Zeiss) under a Cy5
filter.
Macrophage Polarization and Supernatant Cytokine
Assay
BMDM were seeded in 6-well plates at 26106 cells/well and
polarized for 48 hours with the addition of 50 ng/ml LPS (List
Biological Labs) and 50 ng/ml IFNc (Cedarlane) for M1, or
40 ng/ml IL-4 (R&D Systems) for M2 at 37uC in a 5% CO2
humidified atmosphere. Cells were re-plated in triplicate in 96-well
plates, 86105 cells/well, in media containing 20 mg/ml DMXAA
or DMSO control for 24 hours. Supernatants were subjected to a
mouse 32-plex cytokine/chemokine discovery array (Luminex)
(EVE Technologies, Calgary, Alberta).
RT-PCR
Subcutaneous tumors and control spleens were snap frozen in
liquid N2 prior to being homogenized in QIAzol lysis reagent
(Qiagen). M1 and M2 polarized macrophages were treated with
20 mg/ml DMXAA (or dose response) or DMSO vehicle for an
additional 24 hours. In addition, M2 polarized macrophages were
treated with 20 mg/ml or 40 mg/ml 2939-cGAMP (InvivoGen) in
the presence of Lipofectamine-2000 (LF2000, Invitrogen). Cells
were lysed with QIAzol lysis reagent (Qiagen) and RNA was
extracted with chloroform and isopropanol. To make cDNA, 1 mg
of RNA was treated with DNAse (Promega) followed by RT-PCR
with 10 mM dNTPs, random primers (Roche) and Superscript II
reverse transcriptase (Invitrogen). Real-time PCR of cDNAs was
carried out on the LightCycler using the LightCycler FastStart
DNA MasterPLUS SYBR Green kit (Roche). Data were
normalized to b-actin mRNA. Primer sequences were as
previously described [44,54,55].
Statistical Methods
Samples were compared using a student’s t-test, with Welch’s
correction on samples with unequal variance. P values of ,0.05
were considered significant.
Supporting Information
Figure S1 Intracardiac injection of 344SQ-ELuc cells
generated a spectrum of systemic metastases. BLI of mice
after intracardiac injection of 344SQ-ELuc cells at day 4, 7, 10
and 14. Dorsal view (A) and ventral view (B). Histology revealed
cells growing within the heart muscle (C), likely as a result of the
cell leakage at the LV injection site. Other common locations for
tumor growth included lung (D), adrenal gland (E), kidney (F),
visceral fat pad (G), and less frequently liver (H), and spleen (I).
Scale bars = 100 mm (F–G) and 50 mm (C, D, E, H, I).
(TIF)
Figure S2 Clodrolip depletion of macrophages prior to
344SQ-ELuc subcutaneous implantation modestly inhib-
ited tumor formation. (A) BMDM from Clod or EL treated
mice (N=3) at day 10 were collected and stained for CD11b and
F4/80 and subjected to FACS, demonstrating an approximately
50% drop in CD11b+ F4/80+ macrophages as quantified in (B)
(***p,0.001, gated for monocytes). BLI growth rates of
subcutaneous (C; N= 5) and LV (E; N= 8) 344SQ-ELuc tumors
in 129/Sv mice demonstrated a modest lag in tumor formation in
subcutaneous tumors, but produced no difference in the
development of 344SQ-ELuc metastases following clodronate-
mediated macrophage depletion, with tumors still developing
regardless of inoculation route (D, F).
(TIF)
Figure S3 DMXAA did not show direct toxicity against
NSCLC cells in vitro. In vitro cytotoxicity of DMXAA on
344SQ-ELuc cells obtained via MTT assays. Data are represented
as the mean 6 SEM.
(TIF)
Figure S4 Polarization of BMDM. (A) BMDM were treated
with 50 ng/ml LPS and 50 ng/ml IFNc for M1 polarization, or
40 ng/ml IL-4 for M2 polarization. After 48 hours, RNA
transcript levels confirmed polarization had occurred by showing
upregulation of iNOS in M1 macrophages, and Arg-1 in M2
macrophages. (B) Reverse phase protein array analysis of M2
macrophages treated with 20 mg/ml DMXAA for 30 min showed
up-regulation of phosphorylated p65 (N=3, ***p#0.001).
(TIF)
Figure S5 Vessel permeability of subcutaneous versus
metastatic tumors. (A) Phase-contrast and corresponding
fluorescence images of control tissues demonstrate Evans blue
dye outlining the vessels in the lung and kidney, consistent with
low levels of background dye leakage. The vessels in the brain,
however, showed no leakage, consistent with the dyes inability to
cross the blood brain barrier. (B) Representative images of Evans
Blue dye leakage in three different lung tumors, and (C)
subcutaneous tumors. Scale bar = 100 mm.
(TIF)
Figure S6 Quantification of vessel parameters of sub-
cutaneous versus metastatic tumors. (A) There was
decreased vessel connectivity in subcutaneous 344SQ-ELuc
tumors compared to primary adenocarcinoma-derived
p53R172HDg/+ K-rasLA1/+ metastases as well as a decrease in vessel
number (B) (not significant). Vessel surface area/vessel volume (C),
however, was similar between the tumor sites indicating that the
dimensions of the vessels present were comparable. Data
represented as mean 6 SEM.
(TIF)
Figure S7 Summary of DMXAA effects in the murine
NSCLC models. Induction of M2-like TAM repolarization
towards an M1-like phenotype by DMXAA accompanied the
rapid onset of hemorrhagic necrosis of subcutaneous tumors. In
contrast, DMXAA did not exhibit vascular disrupting effects on
either syngeneic metastases or spontaneously arising NSCLC in
tumors in KrasLA1 GEMM model.
(TIF)
Table S1 DMXAA induction of cytokines and chemo-
kines in M1 versus M2 polarized macrophages. Polarized
BMDM (N=3) were treated with DMXAA or DMSO control and
serums were analyzed via cytokine array. Average values are
shown.
(DOCX)
Acknowledgments
We are grateful to Dr. J. Kurie (University of Texas) for the 344SQ cell
line; to Dr. G. Lozano (University of Texas) for the p53R172HDg/+ K-rasLA1/+
mice; and to L. Barclay and M. Villemaire for their excellent technical
STING Agonists Cause M2-To-M1 Repolarization
PLOS ONE | www.plosone.org 12 June 2014 | Volume 9 | Issue 6 | e99988
support. C.M.D. was supported by a Banting and Best Doctoral
Studentship award from Canadian Institutes for Health Research, and
also by an Alberta Innovates-Health Sciences Foundation award. F.R.J.
was the recipient of a Canada Research Chairs award.
Author Contributions
Conceived and designed the experiments: FRJ CMD. Performed the
experiments: CMD MA. Analyzed the data: FRJ CMD MA. Contributed
reagents/materials/analysis tools: RAS. Wrote the paper: CMD FRJ.
References
1. Ribatti D, Nico B, Crivellato E, Roccaro AM, Vacca A (2007) The history of the
angiogenic switch concept. Leukemia 21: 44–52.
2. McKeage MJ, Baguley BC (2010) Disrupting established tumor blood vessels: an
emerging therapeutic strategy for cancer. Cancer 116: 1859–1871.
3. Tozer GM, Kanthou C, Baguley BC (2005) Disrupting tumour blood vessels.
Nat Rev Cancer 5: 423–435.
4. Jameson MB, Thompson PI, Baguley BC, Evans BD, Harvey VJ, et al. (2003)
Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid
(DMXAA), a novel antivascular agent. Br J Cancer 88: 1844–1850.
5. Zhao L, Ching L-M, Kestell P, Baguley BC (2002) The antitumour activity of
5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout
mice. British Journal of Cancer 87: 465–470.
6. Wang LC, Thomsen L, Sutherland R, Reddy CB, Tijono SM, et al. (2009)
Neutrophil influx and chemokine production during the early phases of the
antitumor response to the vascular disrupting agent DMXAA (ASA404).
Neoplasia 11: 793–803.
7. Baguley BC, Siemann DW (2010) Temporal aspects of the action of ASA404
(vadimezan; DMXAA). Expert Opin Investig Drugs 19: 1413–1425.
8. Head M, Jameson MB (2010) The development of the tumor vascular-disrupting
agent ASA404 (vadimezan, DMXAA): current status and future opportunities.
Expert Opin Investig Drugs 19: 295–304.
9. Siemann DW, Mercer E, Lepler S, Rojiani AM (2002) Vascular targeting agents
enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer
99: 1–6.
10. Ching L-M, Cao Z, Kieda C, Zwain S, Jameson MB, et al. (2002) Induction of
endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-
acetic acid. British Journal of Cancer 86: 1937–1942.
11. Sun J, Wang LC, Fridlender ZG, Kapoor V, Cheng G, et al. (2011) Activation of
mitogen-activated protein kinases by 5,6-dimethylxanthenone-4-acetic acid
(DMXAA) plays an important role in macrophage stimulation. Biochem
Pharmacol 82: 1175–1185.
12. Moilanen E, Thomsen LL, Miles DW, Happerfield DW, Knowles RG, et al.
(1998) Persistent induction of nitric oxide synthase in tumours from mice treated
with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer
77: 426–433.
13. McKeage MJ, Von Pawel J, Reck M, Jameson MB, Rosenthal MA, et al. (2008)
Randomised phase II study of ASA404 combined with carboplatin and
paclitaxel in previously untreated advanced non-small cell lung cancer.
Br J Cancer 99: 2006–2012.
14. Lorusso PM, Boerner SA, Hunsberger S (2011) Clinical development of vascular
disrupting agents: what lessons can we learn from ASA404? J Clin Oncol 29:
2952–2955.
15. Lara PN Jr, Douillard JY, Nakagawa K, von Pawel J, McKeage MJ, et al. (2011)
Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with
or without the vascular disrupting agent vadimezan (ASA404) in advanced non-
small-cell lung cancer. J Clin Oncol 29: 2965–2971.
16. Fruh M, Cathomas R, Siano M, Tscherry G, Zippelius A, et al. (2012)
Carboplatin and Paclitaxel Plus ASA404 as First-Line Chemotherapy for
Extensive-Stage Small-Cell Lung Cancer: A Multicenter Single Arm Phase II
Trial (SAKK 15/08). Clin Lung Cancer.
17. Pili R, Rosenthal MA, Mainwaring PN, Van Hazel G, Srinivas S, et al. (2010)
Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-
4-acetic acid) to docetaxel in CRMPC. Clin Cancer Res 16: 2906–2914.
18. Tijono SM, Guo K, Henare K, Palmer BD, Wang L-CS, et al. (2013)
Identification of human-selective analogues of the vascular-disrupting agent 5,6-
dimethylxanthenone-4-acetic acid (DMXAA). British Journal of Cancer 108:
1306–1315.
19. Prantner D, Perkins DJ, Lai W, Williams MS, Sharma S, et al. (2012) 5,6-
Dimethylxanthenone-4-acetic acid (DMXAA) activates stimulator of interferon
gene (STING)-dependent innate immune pathways and is regulated by
mitochondrial membrane potential. J Biol Chem 287: 39776–39788.
20. Conlon J, Burdette DL, Sharma S, Bhat N, Thompson M, et al. (2013) Mouse,
but not human STING, binds and signals in response to the vascular disrupting
agent 5,6-dimethylxanthenone-4-acetic acid. J Immunol 190: 5216–5225.
21. Kim S, Li L, Maliga Z, Yin Q, Wu H, et al. (2013) Anticancer Flavonoids Are
Mouse-Selective STING Agonists. ACS Chem Biol.
22. Downey CM, Singla AK, Villemaire ML, Buie HR, Boyd SK, et al. (2012)
Quantitative Ex-Vivo Micro-Computed Tomographic Imaging of Blood Vessels
and Necrotic Regions within Tumors. PLoS One 7: e41685.
23. Zheng S, El-Naggar AK, Kim ES, Kurie JM, Lozano G (2007) A genetic mouse
model for metastatic lung cancer with gender differences in survival. Oncogene
26: 6896–6904.
24. Gibbons DL, Lin W, Creighton CJ, Rizvi ZH, Gregory PA, et al. (2009)
Contextual extracellular cues promote tumor cell EMT and metastasis by
regulating miR-200 family expression. Genes Dev 23: 2140–2151.
25. Bondareva A, Downey CM, Ayres F, Liu W, Boyd SK, et al. (2009) The lysyl
oxidase inhibitor, beta-aminopropionitrile, diminishes the metastatic coloniza-
tion potential of circulating breast cancer cells. PLoS One 4: e5620.
26. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, et al. (2001)
Somatic activation of the K-ras oncogene causes early onset lung cancer in mice.
Nature 410: 1111–1116.
27. Zeisberger SM, Odermatt B, Marty C, Zehnder-Fjallman AH, Ballmer-Hofer
K, et al. (2006) Clodronate-liposome-mediated depletion of tumour-associated
macrophages: a new and highly effective antiangiogenic therapy approach.
Br J Cancer 95: 272–281.
28. Chen Z, Cheng K, Walton Z, Wang Y, Ebi H, et al. (2012) A murine lung
cancer co-clinical trial identifies genetic modifiers of therapeutic response.
Nature 483: 613–617.
29. Singh M, Murriel CL, Johnson L (2012) Genetically engineered mouse models:
closing the gap between preclinical data and trial outcomes. Cancer Res 72:
2695–2700.
30. Wu Q, Quan H, Xu Y, Li Y, Hu Y, et al. (2012) p38 mitogen-activated protein
kinase is required for the antitumor activity of the vascular disrupting agent 5,6-
dimethylxanthenone-4-acetic acid. J Pharmacol Exp Ther 341: 709–717.
31. Rolny C, Mazzone M, Tugues S, Laoui D, Johansson I, et al. (2011) HRG
inhibits tumor growth and metastasis by inducing macrophage polarization and
vessel normalization through downregulation of PlGF. Cancer Cell 19: 31–44.
32. Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, et al. (2008) ‘‘Re-
educating’’ tumor-associated macrophages by targeting NF-kappaB. J Exp Med
205: 1261–1268.
33. Sica A, Mantovani A (2012) Macrophage plasticity and polarization: in vivo
veritas. J Clin Invest 122: 787–795.
34. Barber GN (2014) STING-dependent cytosolic DNA sensing pathways. Trends
Immunol 35: 88–93.
35. McWhirter SM, Barbalat R, Monroe KM, Fontana MF, Hyodo M, et al. (2009)
A host type I interferon response is induced by cytosolic sensing of the bacterial
second messenger cyclic-di-GMP. J Exp Med 206: 1899–1911.
36. Burdette DL, Monroe KM, Sotelo-Troha K, Iwig JS, Eckert B, et al. (2011)
STING is a direct innate immune sensor of cyclic di-GMP. Nature 478: 515–
518.
37. Seshadri M, Toth K (2009) Acute vascular disruption by 5,6-dimethylxanthe-
none-4-acetic Acid in an orthotopic model of human head and neck cancer.
Transl Oncol 2: 121–127.
38. Liu JJ, Ching LM, Goldthorpe M, Sutherland R, Baguley BC, et al. (2007)
Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing
chemically induced primary mammary tumours. Cancer Chemother Pharmacol
59: 661–669.
39. Bibby MC, Phillips RM, Double JA (1989) Influence of site on the
chemosensitivity of transplantable murine colon tumours to flavone acetic acid
(LM975, NSC 347512). Cancer Chemother Pharmacol 24: 87–94.
40. Dubensky TW Jr, Kanne DB, Leong ML (2013) Rationale, progress and
development of vaccines utilizing STING-activating cyclic dinucleotide
adjuvants. Therapeutic Advances in Vaccines 1: 131–143.
41. Andersson U, Tracey KJ (2011) HMGB1 is a therapeutic target for sterile
inflammation and infection. Annual review of immunology 29: 139–162.
42. Qian BZ, Pollard JW (2010) Macrophage diversity enhances tumor progression
and metastasis. Cell 141: 39–51.
43. Schmieder A, Michel J, Schonhaar K, Goerdt S, Schledzewski K (2012)
Differentiation and gene expression profile of tumor-associated macrophages.
Semin Cancer Biol 22: 289–297.
44. Standiford TJ, Kuick R, Bhan U, Chen J, Newstead M, et al. (2011) TGF-beta-
induced IRAK-M expression in tumor-associated macrophages regulates lung
tumor growth. Oncogene 30: 2475–2484.
45. Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP (2005)
Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells
towards tumor rejection. Cancer Res 65: 3437–3446.
46. Fridlender ZG, Jassar A, Mishalian I, Wang L-C, Kapoor V, et al. (2013) Using
macrophage activation to augment immunotherapy of established tumours.
British Journal of Cancer 108: 1288–1297.
47. Allavena P, Mantovani A (2012) Immunology in the clinic review series; focus on
cancer: tumour-associated macrophages: undisputed stars of the inflammatory
tumour microenvironment. Clin Exp Immunol 167: 195–205.
48. Fridlender ZG, Albelda SM (2013) Modifying tumor-associated macrophages:
An important adjunct to immunotherapy. OncoImmunology 2: e26620.
49. Francia G, Cruz-Munoz W, Man S, Xu P, Kerbel RS (2011) Mouse models of
advanced spontaneous metastasis for experimental therapeutics. Nature Reviews
Cancer 11: 135–141.
50. Politi K, Pao W (2011) How genetically engineered mouse tumor models provide
insights into human cancers. J Clin Oncol 29: 2273–2281.
STING Agonists Cause M2-To-M1 Repolarization
PLOS ONE | www.plosone.org 13 June 2014 | Volume 9 | Issue 6 | e99988
51. Peifer M, Ferna´ndez-Cuesta L, Sos ML, George J, Seidel D, et al. (2012)
Integrative genome analyses identify key somatic driver mutations of small-cell
lung cancer. Nature Genetics 44: 1104–1110.
52. Liu G, McDonnell TJ, Montes de Oca Luna R, Kapoor M, Mims B, et al. (2000)
High metastatic potential in mice inheriting a targeted p53 missense mutation.
Proc Natl Acad Sci U S A 97: 4174–4179.
53. Jamniczky HA, Hallgrimsson B (2011) Modularity in the skull and cranial
vasculature of laboratory mice: implications for the evolution of complex
phenotypes. Evol Dev 13: 28–37.
54. Overbergh L, Valckx D, Waer M, Mathieu C (1999) Quantification of murine
cytokine mRNAs using real time quantitative reverse transcriptase PCR.
Cytokine 11: 305–312.
55. Gobert AP, Cheng Y, Wang JY, Boucher JL, Iyer RK, et al. (2002) Helicobacter
pylori induces macrophage apoptosis by activation of arginase II. J Immunol
168: 4692–4700.
STING Agonists Cause M2-To-M1 Repolarization
PLOS ONE | www.plosone.org 14 June 2014 | Volume 9 | Issue 6 | e99988
